<?xml version="1.0" encoding="UTF-8"?>
<p>Medicines are authorized mainly based on the supportive data coming from clinical trials that are typically of limited duration and sample size, exclude the most severely ill patients, and limit the number of comedications.
 <xref rid="pds5133-bib-0002" ref-type="ref">
  <sup>2</sup>
 </xref> Those controlled conditions significantly differ from the ones encountered in real life and may consequently hamper the possibility of identifying in the pre‚Äêauthorization period important serious adverse drug reactions. For instance, rare, delayed reactions or those that occur due to an interaction with other medicinal products or comorbidities might only emerge after a medicine is released on the market, when the exposure is significantly larger, for a longer duration and in less ideal settings.
</p>
